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Abstract: The concept of the adenoma-carcinoma sequence, as first espoused by Morson et al. whereby the development 
of colorectal cancer is dependent on a stepwise progression from adenomatous polyp to carcinoma is well documented.  
Initial studies of the genetics of inherited colorectal cancer susceptibility concentrated on the inherited colorectal cancer 
syndromes, such as Familial Adenomatous Polyposis (FAP) and Lynch Syndrome (also known as HNPCC). These syn-
dromes, whilst easily characterisable, have a well understood sequence of genetic mutations that predispose the sufferer to 
developing colorectal cancer, initiated for example in FAP by the loss of the second, normal allelle of the tumour supres-
sor APC gene. Later research has identified other inherited variants such as MUTYH (MYH) polyposis and Hyperplastic 
Polyposis Syndrome.  
Recent research has concentrated on the pathways by which colorectal adenomatous polyps not due to one of these known 
inherited susceptibilities undergo malignant transformation, and determination of the types of polyps most likely to do so. 
Also, why do individuals in certain families have a predisposition to colorectal cancer.  
In this article, we will discuss briefly the current state of knowledge of the genomics of the classical inherited colorectal 
cancer syndromes. We will also discuss in detail the genetic changes in polyps that undergo malignant transformation as 
well as current knowledge with regards to the epigenomic changes found in colorectal polyps. 
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INTRODUCTION 
The model of an adenoma, thought to be initiated by a 
DNA mutation caused by an environmental agent, promoted 
by further exposure to the same or a different environmental 
agent and progression into a carcinoma by a carcinogenic 
agent was first espoused by Morson et al. [1] in 1978. It was 
also hypothesised in a later paper [2] that certain forms of 
polyposis had a hereditable component, namely familial ade-
nomatous polyposis, multiple juvenile polyposis and Peutz-
Jegher syndrome.  
Although there is strong evidence for the development of 
carcinoma from a precursor adenomatous polyp there is no 
definitive evidence for this. It has been estimated that 30-
40% of the Western population will develop some adenomas 
at some stage in their lifetime [3, 4], usually after 40 years of 
age. Of these patients, only approximately 3% will go on to 
develop colorectal cancer. 
There is a large body of evidence regarding the molecular 
genetic changes that occur in colorectal carcinogenesis. Ini-
tial studies have concentrated on the molecular and genomic 
changes in easily characterisable inherited colorectal cancer 
syndromes such as Familial Adenomatous Polyposis (FAP), 
Lynch Syndrome (also known as Hereditary Non-Polyposis 
Colorectal Cancer, HNPCC), the more recently characterised 
MYH polyposis, Peutz-Jegher Syndrome, PTEN Hamartoma  
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Syndrome, Juvenile Polyposis Syndrome and Hyperplastic 
Polyposis Syndrome.  
It has been shown that there are several different series of 
molecular pathways that benign adenomatous polyps follow 
in their progression from benign polyp to malignant cancer. 
These pathways include the Chromosomal Instability path-
way (CIN), the Microsatellite Instability Pathway (MSI) and 
the “Serrated Adenoma” pathway. 
THE INHERITED COLORECTAL CANCER SYN-
DROMES 
Familial Adenomatous Polyposis (FAP) 
FAP is a polyposis syndrome, inherited in an autosomal 
dominant manner with almost 100% penetrance [5]. It was 
the first inherited polyposis syndrome to be clinically charac-
terised. It generally presents with total intestinal polyposis 
within the 2nd – 3rd decade of life. Polyps may be asymp-
tomatic, so that patients may initially present with colorectal 
tumours.  
The incidence of FAP is approximately 1:10,000 [6]. It 
forms a very small part of the total colorectal carcinoma in-
cidence, estimated at less than one percent. There is no dif-
ference between men and women in incidence.  
Patients with FAP present with total colonic polyposis, 
initially affecting the colon, with the number of polyps in-
creasing over time to between 100-5000. The polyps them-
selves are adenomatous polyps which are indisguishable 
from sporadic adenomas [5]. However, the incidence of mi-
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croadenomas is much greater in patients with FAP [7]. The 
number of polyps increases the risk of colorectal carcino-
genesis greatly, compared to the single adenoma typically 
found in sporadic cases. The lifetime risk of colorectal car-
cinogenesis in untreated FAP patients is 100%. 
FAP is caused by germline mutations in the APC (ade-
nomatous polyposis coli) gene. Usually, affected individuals 
acquire a defective copy of the APC gene from the affected 
parent, with a somatic mutation of the other copy of the gene 
causing the initiation of polyposis. However, approximately 
30% [5] of cases of FAP present as new germline mutations 
in the APC gene.  
The germline mutations found in the APC gene in FAP 
are very similar to those found in sporadic adenomas and 
consist of either frameshift or nonsense mutations leading a 
premature stop codon and truncuation of the APC protein 
product, leading to uncontrolled cellular proliferation. Polyps 
are initiated by somatic mutation or loss of the normal allele 
in the susceptible tissue, i.e. colonic epithelium. The mecha-
nism by which mutation of the APC gene leads to colorectal 
carcinogenesis is discussed later in this paper. 
Another form of FAP is the attenuated APC variant, 
known as AAPC. This differs from the standard FAP in that 
although the risk of colorectal carcinogenesis is almost 
100%, patients tend to develop polyposis later in life (3rd-
5th decade of life) and develop fewer polyps [8]. 
Mutations in two genes can cause AAPC. The first are 
mutations in the 3’ and 5’ end of the APC gene and in the 
alternatively spliced exon 9 of the APC gene. AAPC may 
also be caused by mutations in MutYH (human MutY homo-
logue), also known as MYH. Germline mutations in the 
MYH gene (autosomal recessive inheritance) have been 
shown to be present in the absence of germline mutations in 
the APC gene in patients with polyposis, and are discussed 
further below. 
Lynch Syndrome (HNPCC) 
Lynch syndrome (also known as Hereditary non-poly- 
posis colorectal cancer syndrome) is a autosomnal domi-
nantly inherited cancer syndrome characterised by early on-
set of colorectal cancer as well as carcinomas derived from 
adenomatous tissue such as colorectal endometrial, ovarian, 
gastric and urinary tract (renal pelvis and ureteric) carcinoma 
[9, 10]. According to the published literature, it is the com-
monest form of hereditary colorectal cancer, with an inci-
dence estimated to be between 1-6% of colorectal carcinoma. 
The mutations characterised in Lynch Syndrome are in 
DNA mismatch repair (MMR) enzymes. The MMR genes 
mutated in the germline in HNPCC have been identified so 
far as hMSH2 (located on 2p), hMLH1 (located on 3p), 
hPMS1, hPMS2 and hMSH6. Over 60% of cases of HNPCC 
are caused by mutations in hMSH2 and hMLH1 [11, 12]. 
A genetic linkage analysis of Swedish Lynch Syndrome 
families identified the position of the MLH1 locus on 3p21 
[13, 14]. hMLH1 encodes the human homologue of the bac-
terial MutL gene. PMS1 and PMS2 are two additional MutL 
homologues, located on 2q31-33 and 7p22 respectively. Un-
like FAP, Lynch syndrome is very rarely caused by a de 
novo germline mutation in an MMR gene. 
hMSH2 encodes for a human homologue to the bacterial 
MutS gene and is responsible for mismatch binding [15, 16]. 
It is part of the complex hMutS? which consists of MSH2 
and MSH6, the genes for both are found at 2p21 as shown by 
FISH studies [17]. It is responsible for repair of base-base 
mismatches and 1bp insertion/deletion loops. In the hMutS? 
complex, MSH6 is responsible for mismatch recognition.  
MLH1 combines with the protein product of hPMS2 to 
form the hMutL? complex that acts as an endonuclease in-
volved in the mismatch repair system [18].  
The MMR pathway is also thought to be involved in the 
pathogenesis of sporadic colorectal cancer and is discussed 
later.  
MYH Polyposis  
MYH polyposis differs from the classical clinical poly-
posis phenotype in that although the risk of colorectal car-
cinogenesis is almost 100%, patients tend to develop poly-
posis later in life (3rd-5th decade of life) and do not develop 
as great a number of polyps [8]. 
This form of AAPC is caused by germline mutations in 
MutYH (human MutY homologue), also known as the MYH 
gene, mutated in the absence of germline mutations in the 
APC gene [19-21]. It is located on 1p32.1.  
The MYH gene codes for a protein product of a base ex-
cision repair enzyme [8]. In the process of normal aerobic 
metabolism, 7,8-dihydro-8-oxoguanine (8-oxoG) forms that 
can mis-pair with adenine. This mis-pairing leads to a trans-
version of G:C to T:A. The MYH gene protein product is a 
DNA glycosylase that excises the abnormal 8-oxoG from the 
adenine base.  
The presence of germline MYH gene mutations were first 
characterised in “Family N” by Al-Tassan et al. [19]. They 
found that three out of seven siblings in the family were af-
fected by an AAPC like phenotype with colorectal carci-
noma and polyps in the absence of a germline mutation in 
APC but with somatic mutation of APC characterised by G:C 
to T:A transversions, suggesting a germline mutation leading 
to a defect of repair of 8-oxoG-related mutations. It was 
noted that for the phenotype of this mutation to occur; both 
copies of the defective MYH gene had to be inherited, mak-
ing the inheritance recessive in nature. 
Studies of patients with FAP-like and AAPC-like pheno-
types with no demonstrable germline mutation in the APC 
gene have shown approximately up to 25% carry bi-allelic 
mutations of the MYH gene [22-24]. In a study by Sieber et 
al. [22] it was found in 152 patients with between 3-100 
adenomas that 14 patients had bi-allelic mutations in the 
MYH gene but interestingly no patient who possessed bi-
allelic mutations had severe (>1000) polyposis. 
Peutz-Jegher Syndrome 
Peutz-Jegher Syndrome (PJS) is an inherited polyposis 
syndrome characterised by multiple hamartomatous polyps  
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in the GI tract associated with mucocutaneous pigmenta-
tion, especially of the vermillion border of the lips. Its inci-
dence is estimated at approximately 1 in 150,000 [25]. The 
clinical manifestations occur in the 1
st
-2
nd
 decade of life, and 
patients present with polyp-related symptoms such as PR 
bleeding, intussusception, abdominal pain and bowel ob-
struction [26], although other features such as buccal pig-
mentation may develop earlier, and may also fade.  
A meta-analysis of published data on Peutz-Jegher Syn-
drome [27] found that the risk ratio for developing any type 
of cancer was greater than 15, with colonic cancer having a 
specific risk ratio of 84.  
PJS is due to a germline mutation of the tumour suppres-
sor gene STK11 [28]. STK11 encodes a serine-threonine 
kinase that controls cellular proliferation and also has a role 
in responding to decreased cellular energy levels [29]. In the 
regulation of energy levels the protein product of STK11 acts 
in a pathway to inhibit AMP-activated protein kinase which 
then signals downstream to inhibit the mTOR (mammalian 
target of rapamycin) pathway [30]. This leads to the dysregu-
lation of the mTOR pathway and the initiation of polyposis.  
PTEN Hamartoma Syndrome (PHTS) 
PHTS is a group name given to a group of disorders that 
are all caused by germline mutations of the tumour suppres-
sor gene PTEN(Phosphatase and Tensin homolog) [31]. 
These disorders consist of Cowden Syndrome, Bannayan-
Riley-Ruvalcaba syndrome (BRRS) and Proteus Syndrome.  
PTEN hamartoma tumour syndrome is caused by a germ-
line mutation of the PTEN tumour suppressor gene [32]. The 
PTEN protein product is a universally expressed phosphatase 
that has activity against lipid and protein components. In its 
lipid component, it helps to regulate levels of phosphoinosi-
tol triphosphate, providing negative feedback to the AKT 
pathway. The PTEN gene has been shown to have a critical 
role [33] in the control of cell growth, proliferation and an-
giogenesis. Further studies have shown that somatic muta-
tions of PTEN are present in colorectal malignancies [34]. 
Gastrointestinal polyps have been shown to be common in 
Cowden Syndrome, and of varied types [35]. 
Juvenille Polyposis Syndrome (JPS) 
JPS is defined as a hamartomatous polyposis syndrome 
affecting both children and, to a lesser extent, adults. To be 
diagnosed, it requires the presence of greater than 3-5 polyps 
in the colon or rectum, or juvenile polyps throughout the GI 
tract or any number of juvenile polyps in an individual who 
has a family history of JPS [36, 37]. JPS polyps have a char-
acteristic appearance [38] and there are usually multiple pol-
yps in the affected GI tract, presenting usually before 20 
years of age [39].  
The genetic mutation underlying JPS involves the trans-
forming growth factor-? pathway [40]. Mutations have been 
described in the SMAD4, BMPR1A and ENG genes. These 
genes all encode for proteins involved in the TGF-? path-
way. As discussed above, the genes SMAD2 and SMAD4 are 
both components of the TGF-? pathway and are involved in 
colorectal carcinogenesis. In a study by Howe et al. [41] 
there was a 20% prevalence of germline mutations of 
BMPR1A and SMAD4. At the present time we do not know 
the prevalence of germline mutations of ENG.  
Hyperplastic Polyposis Syndrome (HPS) 
Hyperplastic polyposis syndrome (HPS) is a recently 
identified, poorly classified entity. Jass et al. in their WHO 
Blue Book classification [42] classified HPS as at least five 
hyperplastic polyps (HPs) proximal to the sigmoid colon, at 
least two of which are >1cm in size, or more than 30 HPs at 
any site in the large bowel. An alternate system from Rashid 
et al. [43] classified HPS as any person with greater than 20 
hyperplastic polyps in their large bowel.  
The precise molecular mechanism that underlies HPS has 
not currently been determined. Several studies have shown a 
variety of genetic changes within these hyperplastic polyps, 
including increased frequency of chromosomal 1p allelic 
loss [43], somatic BRAF [44] (80% of HP’s) and k-RAS2 
(10% of HP’s) mutations [44]. MSI has also been shown to 
be present at only low frequency in HP’s, at approximately 
2% [44]. A recent study on HPS in the Ashkenazi Jewish 
population mapped a high penetrance gene, CRAC1 to 
15q13.3–q14 [45]. 
It has been shown that patients with the characteristics of 
HPS have an increased risk of developing colorectal carci-
noma [46-48].  
The Somatic Genetic Pathways in Sporadic Colorectal 
Cancer 
Using the classical colorectal cancer syndromes such as 
FAP and Lynch Syndrome as a paradigm, significant knowl-
edge has been gained regarding the development of sporadic 
cases of colorectal cancer. Several pathways have been de-
lineated, based on the molecular “signatures” of both colo-
rectal cancer, and their precursor lesions.  
The Chromosomal Instability (CIN) Pathway 
Fogel and Vogelstein [49] proposed a model of colorectal 
carcinogenesis suggesting that mutational activation of 
proto-oncogenes to oncogenes as well as mutational inacti-
vation of tumour suppression genes in a stepwise sequence 
of events leading to colorectal carcinogenesis.  
In their model, it was suggested that mutation of the k-ras 
proto-oncogene leading to activation of the oncogene as well 
as mutational inactivation of tumour suppressor genes exist-
ing on chromosomes 5q (APC), 7p (p53) and 18q (SMAD4) 
were the key initiators of colorectal carcinogenesis. They 
also hypothesised that DNA hypomethylation, believed to 
have a role in the silencing and expression of genes, played a 
part in this mechanism.  
Several important genes have been characterised as being 
involved in the Chromosomal Instability pathway, namely 
the APC, k-ras, p53 genes and mutations in the TGF-? sig-
nalling pathway. 
Adenomatous Polyposis Coli (APC) 
The APC tumour suppressor gene is thought to have a 
pivotal role in the initiation of CRC. It was first character-
ised in the germline of patients suffering from Familial Ade-
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nomatous Polyposis (FAP). The APC gene is located on 
chromosome 5q21 [50]. It encodes a 312 kDa protein com-
posing of 2843 amino acids. The protein product has several 
functions and interacts with important proteins controlling 
cellular function including ?-catenin, glycogen synthase 
kinase (GSK), end-binding protein (EB) 1 and Bub kinase 
[51-53]. The first two proteins are intimately involved in the 
Wnt signalling pathway. 
APC is important in regulation of intracellular ? catenin 
levels. ? catenin binds to T-cell factor transcription factors 
and leads to activation of gene transcription. The wild type 
(non-mutated) APC protein product binds to ?-catenin, GSK-
3 ? ? and CK1?/ ? using an axin/conductin skeleton [54]. This 
leads to increased ?-catenin breakdown by promoting phos-
phorylation of ?-catenin leading to its degradation via the 
ubiquitin-proteasome pathway. The mutated form of APC 
cannot bind to ?-catenin which accumulates [51, 55, 56].  
When intracellular ?-catenin levels rise as a result of 
faulty APC function, this promotes carcinogenesis through 
the Wnt pathway which is a key signal transduction pathway 
involved in the homeostasis of colonic epithelium.  
The Wnt family of glycoproteins are involved in activa-
tion of the Wnt /? ?-catenin pathway [57]. Wnt secretion is 
controlled by the Wntless/evenness transmembrane protein 
[58]. The Wnt glycoprotein binds to the transmembrane re-
ceptor frizzled and low-density lipoprotein receptor-related 
protein LRP-5/6 which leads to phosphorlation of LRP by 
GSK-3 ?  and CK1? thus causing recruitment of axin to the 
cell membrane [59].  
Axin is then degraded preventing integration into the 
GSK-3? / ?-catenin/axin complex and thus causing a rise in 
intracellular ?-catenin levels [59]. This leads to stabilised ?-
catenin entering the nucleus of the cell, associating with 
TCF/LEF transcription factors and causing activation of 
downstream Wnt target genes.  
Mutant APC has been shown in rat models to allow nu-
clear accumulation of ?-catenin at the base of normal colonic 
crypts leading to permanent stimulation of the Wnt pathway 
[60] which causes hyperproliferation of colonic epithelium, 
thus increasing the likelihood of dysplasia and progression to 
malignancy [61]. 
APC protein may play a role in the control of chromoso-
mal division through the formation of microtubules [62] as 
well as a companion protein, EB-1, a protein associated with 
the C-terminal end of the APC protein [63]. Microtubules are 
important in cell division as they link to the kinetochore. 
Recent evidence shows that non-mutated APC protein helps 
to stabilise kinetochore microtubules and allows them to 
attach to the chromosomes [64]. 
The most common mutation in the APC gene is a prema-
ture stop codon caused by a point mutation leading to a trun-
cuated protein [65]. Approximately 60% of point mutations 
occur within the mutation cluster region at the 3’ end of the 
APC gene [54]. APC mutations have been observed in 30-
70% of sporadic adenomas and in 34-72% of sporadic carci-
nomas [65-68]. APC mutations have been shown to occur at 
a similar frequency at all stages of colorectal carcinogenesis, 
suggesting that they are an early event.  
However, allelic loss of APC has been shown to increase 
in frequency as there is progression towards carcinoma [69]. 
Adenomas as small as 0.5cm carry APC mutations [70], rein-
forcing the theory that these are initiators of a cascade of 
genetic changes leading to carcinogenesis. 
K-ras mutations 
K-ras is an oncogene thought to play an important role in 
the colorectal adenoma-carcinoma sequcence. The oncogene 
codes for a 21kDa protein, ras p21, which is involved in sig-
nal transduction of regulatory pathways involved in cell dif-
ferentiation [71, 72].  
When expressed it is a GTP-binding protein located on 
the cytoplasmic aspect of the cell membrane and has intrin-
sic GTPase activity that is regulated by other proteins [73]. It 
has been found that all carcinogenic mutations of the ras 
oncogene affect codons in the domain responsible for GTP 
binding leading to a decrease in the GTPase activity, causing 
permanent activation of the ras protein [73]. This causes un-
constrained cellular proliferation.  
Mutations in k-ras have been found in 35-42% of colo-
rectal adenomas and carcinomas [74, 75]. These studies also 
demonstrated that k-ras mutation is more common as the 
size of the adenoma increased. 54 small benign lesions of the 
colorectum were analysed in a study by Jen et al. [75] who 
demonstrated that 82% of the adenomas in the group demon-
strated APC mutations, but none of the hyperplastic polyps 
possessed this mutation. In both groups of polyps there was 
approximately a 22-25% rate of k-ras mutation but in dys-
plastic lesions this k-ras mutation was always associated 
with an APC mutation, suggesting that k-ras mutations may 
be insufficient on their own to initiate carcinogenesis.  
Biopsies of normal colonic mucosa in patients who have 
had resections for colonic carcinoma have shown a much 
increased frequency of k-ras mutations in the normal mu-
cosa. It has been suggested by Zhu et al. [76] and Minamoto 
et al. [77] that this may be a potential marker for stratifying 
risk in patients with colorectal carcinoma.  
p53 
p53 is known as the “Guardian of the Genome” because 
it blocks cell proliferation in the presence of DNA damage as 
well as promoting DNA repair and causing apoptosis if the 
repair is insufficient [78].  
The p53 gene is located on the short arm of chromosome 
17 and was thought in initial cytogenetic studies to be re-
sponsible for the initiation of colorectal cancer [79, 80]. The 
relationship between p53 and aneuploidy is more complex as 
studies have shown aneuploidy not associated with p53 
overexpression [81], chromosomal abnormalities in patients 
with normal (wild-type) p53 [82], and mutant p53 in cells 
with normal chromosomal ploidy [83]. It is hypothesised that 
the reason for such large variations is that the different muta-
tions have different effects on the tumour phenotype because 
of different effects on the downstream part of the p53 path-
way [84]. 
The mechanism of carcinogenesis with respect to p53 
and colorectal cancer is thought to be functional inactivation 
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due to either mis-sense muations in the DNA binding do-
main of p53 or oncogenic viral interaction with p53 [85, 86]. 
These mutations lead to accumulation of p53 in cells, as 
mutant p53 is resistant to degradation by proteolysis (by the 
mdm-2-ubiquitin pathway) leading to accumulation in the 
cell [87]. Normal (wild-type) p53 has a very short half life 
and thus does not persist.  
Functional inactivation or alteration of p53 or allelic loss 
at 17p has been shown to be present in between 4-26% of 
colorectal adenomas [88, 89]. It is has also been shown in 
50% of invasive foci in adenomatous polyps [89] and in 50-
75% of adenocarcinomas of the colon [90-92]. It is hypothe-
sised that functional inactivation of the p53 protein is one of 
the factors necessary for the transition from adenoma – car-
cinoma [84] in the colon.  
18q (SMAD4) Loss / TGF- ?  Pathway Mutations 
Originally mutations in a tumour suppressor gene provi-
sionally known as the “Deleted in Colorectal Carcinoma” 
(DCC) gene were thought to be one of the mutations 
responsible for initiation of colorectal carcinogenesis [93], 
because it was frequently lost in colorectal cancer and was 
found to be located on chromosome 18q.  
Further analysis showed the DCC gene actually coded for 
a component of the receptor complex that mediated the ef-
fects of netrin-1, a molecule involved in axon guidance [94], 
which seemed an unlikely function for this role. In a study of 
57 colorectal cancers, it was found that there were almost 
never any mutations in the DCC gene in human colorectal 
tumours showing 18q allelic loss [95].  
Mouse knockout models of APC/DCC have shown that 
loss of the DCC gene in mice that have adenomas initiated 
by APC loss causes a bias towards highly dysplastic adeno-
mas [96]. The DCC gene possesses pro-apoptotic activity, 
thought to be due to cleavage by a capsase (cysteine prote-
ase) exposing a pro-apoptotic domain on the DCC receptor, 
which is inhibited by netrin-1. Over-expression of netrin-1 in 
mouse models, coupled with loss of the APC gene has been 
shown to suppress pro-apoptotic activity and is postulated to 
promote carcinogenesis.  
However, studies of human colorectal cancers [96] have 
shown that only 7% of colorectal cancers have over-
expression of netrin-1, implying that loss of the DCC recep-
tor complex by 18q allelic loss or direct mutation may not 
confer the same selective advantage towards human colorec-
tal cancer cells.  
Characterisation and identification of other tumour sup-
pressor genes in the 18q region revealed two candidate 
genes, namely SMAD2 and SMAD4. SMAD proteins are 
human homologs of the drosophila protein, mothers against 
decapentaplegic (MAD) and the C. elegans protein SMA. 
SMAD4 was originally identified as a candidate gene that 
is mutated in early pancreatic carcinoma [97]. The protein 
product of the SMAD4 gene codes for intracellular mediators 
of the transforming growth factor (TGF) ? pathway [98, 99]. 
This is an inhibitory pathway that is responsible for exerting 
a wide range of effects including regulation of cell growth, 
differentiation and apoptosis and has been implicated in a 
wide range of human cancers [99].  
TGF- ? ? signalling is initiated via the binding of TGF- ? ? 
to type II TGF- ? (TGFBR2) receptors. The commonest iso-
form of TGF- ?, TGFB1 binds to TGFBR2 which then leads 
to recruitment via phosphorylation of the type I TGF- ? re-
ceptor (TGFBR1) leading to activation of TGFBR1 protein 
kinase. This causes phosphorylation of SMAD2 and 
SMAD3, two transcription factors that then bind to and acti-
vate SMAD4. These complexes then migrate to the nucleus 
where they activate a series of TGF- ? responsive genes 
[100, 101]. These genes typically include the cell-cycle 
checkpoint genes CDKN1A (p21), CDKN1B (p27) and 
CDKN2B (p15), which when activated cause cell cycle arrest 
[102]. Therefore the TGF- ? pathway acts as a tumour sup-
pressor pathway in normal colonic epithelium. 
In studies of colorectal carcinomas excised at surgery, 
mutations of the SMAD4 and SMAD2 genes have been ob-
served [103-105]. A study by Zhou et al. [106] took human 
colorectal cancer cell lines and used targeted deletion to in-
activate the SMAD4 gene. They found that this prevented 
transduction of the TGF- ? pathway leading to uncontrolled 
cellular proliferation. The ubitquitin-proteasome pathway 
has been implicated as being responsible for accelerated 
breakdown of the mutated SMAD2/4 protein product, again 
leading to uncontrolled cell proliferation [100]. 
Conversely, it has been found that at the later stages of 
colorectal cancer development, the TGF- ? pathway actually 
acts to promote invasion and metastasis, shown in several 
experimental models where colonic epithelial cells were ex-
posed to high levels of TGF- ? which induced malignant 
transformation [107] as well as invasion causing metastasis 
[108]. This is thought to be due to the fact that TGF- ? regu-
lates the production of growth factors including TGF- ?, 
FGF and EGF [101], as well as the fact that tumour cells at 
an advanced state of development become resistant to the 
inhibitory effect of the TGF- ? pathway. 
The Microsatellite Instability Pathway (MSI) 
Microsatellites, also known as simple sequence repeats 
are polymorphic loci present in all cellular DNA. They con-
sist of tandem repeats, usually of between 1-4 base pairs in 
length, repeated many times [11].  
Microsatellites are highly variable and prone to mutation, 
due to slipped strand mispairing (slippage) during DNA rep-
lication. Mutations in microsatellites are usually repaired by 
mismatch repair (MMR) enzymes, but when these repair 
enzymes have been inactivated by mutation of the gene en-
coding the MMR enzyme, the microsatellite mutations ac-
cumulate as DNA is replicated [11], leading to “microsatel-
lite instability” (MSI).  
In cells that have inactivated MMR enzymes both micro-
satellite DNA and nucleotide repeat sequences in other key 
genes, such as cell cycle regulatory genes are at risk. It is on 
this basis that MSI is used a surrogate marker for the state of 
hypermutability or a “mutator phenotype” [109, 110]. 
In sporadic colorectal tumours, germline mutations of 
MMR genes are rare in tumours that are MSI-high, but lack  
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of expression of MLH1 has been found to be very common 
(up to 95%) in sporadic MSI+ tumours and is thought to be 
due to hypermethylation of the promoter region of MLH1 
gene [111]. 
MSI +ve tumours can be further sub-divided into MSI-
high (where there is a high level of instability) or MSI-low 
(where there is a low level of instability). In a paper by 
Dietmaier [14] et al. MSI-high was defined as more than 
20% of loci being unstable and MSI-low defined as less than 
10% of loci being unstable in comparison between the germ-
line DNA and the tumour itself.  
A recent study by Samowitz et al. [112] has only demon-
strated MSI-high in 1.8% of all sporadic adenomas, rising to 
2.5% in proximal adenomas. This is in contrast to patients 
with Lynch Syndrome, where almost all adenomas are found 
to be MSI-H. 
One of the mechanisms hypothesised to cause progres-
sion from adenoma to carcinoma is mutation of mononucleo-
tide repeats in the coding region for the TGF- ? type II re-
ceptor (TGFBR2). This has been found to be mutated by 
inactivation due to hypermethylation of the promoter region 
in over 90% of colorectal cancers showing MSI [113]. In 
sporadic adenomas the earliest stage at which RII mutations 
could be detected was in high grade dysplastic adenomas. In 
adenomas with foci of invasive adenocarcinoma, it was 
noted that the TGFBR2 had mutated in 75% of cases [114]. It 
has been suggested that mutation of TGF-? RII is a critical 
rate limiting step in the transformation from adenoma to car-
cinoma and that this mutation promotes this [84].  
There have also been recent studies that have suggested 
“crosstalk” between the Wnt signalling pathway and the 
TGF-? signalling pathway [115, 116]. This is based on 
knockout mouse models that possess not only APC muta-
tions but SMAD/TGF-? pathway progressing to larger, more 
dysplastic polyps at a much faster rate, suggesting that these 
activation pathways may be synergistic. 
The “Serrated Adenoma Pathway”  
Serrated adenomas are have variant of hyperplastic pol-
yps. They usually occur in the right colon of middle aged 
females and have an increased risk of malignant transforma-
tion [117]. These polyps display alteration of their prolifera-
tive zones, with dilation of the crypts, occasionally extending 
into the muscularis mucosae. The crypts can also herniate 
through the muscularis mucosae, producing an appearance 
similar to invasive carcinoma [118]. Serration is also seen at 
the base of the crypts. 
BRAF Mutations 
RAS proteins are involved in the RAS-RAF-MEK-ERK-
MAP kinase pathway, involved in transducting cellular re-
sponse to growth signals. As shown above, somatic muta-
tions of the RAS gene (k-ras) can cause malignant transfor-
mation. There are three RAF genes that encode ser-
ine/threonine kinases that are regulated by binding to RAS 
[119, 120]. 
Mutations of the BRAF gene have been shown to be an 
alternative route for colorectal carcinogenesis [121]. In a 
study by Davies et al. [121] a panel of primary colorectal 
tumours and colorectal cancer cell lines were screened for 
mutations in BRAF. Over 10% of tumours & cell lines were 
found to have BRAF mutations.  
Mutations in BRAF [121] affect two regions of the BRAF 
kinase domain, namely the activation segment (which pro-
tects the substrate binding site) and the G loop (which medi-
ates the binding of ATP). These mutated forms of BRAF 
have elevated kinase activity and are probably responsible 
for unregulated growth signalling and therefore the initiation 
of carcinogenesis.  
In a study by Chan et al. [122] “serrated” polyps were 
analysed for mutations in BRAF or k-ras. They found of 
these serrated polyps, BRAF mutations were found in 36% of 
hyperplastic polyps(HP), 20% of admixed hyperplastic 
polyp/adenomas(HP/AD) and 100% of serrated adenomas 
(SA). k-ras mutations were found in 18% of HP’s, 60% of 
HP/AD’s and 0% of SA’s. They also showed that 90% of 
serrated polyps that showed dysplasia had mutations in 
BRAF or k-ras and that these acquired mutations were mutu-
ally exclusive, i.e. either BRAF or k-ras was present. 
BRAF mutation V600E is associated with somatic mis-
match repair deficiency (MSI) and found in 40% of the cases 
while in mismatch repair proficient tumors (MSS) the fre-
quency is around 5%. In sporadic MSI cases of colon cancer 
this mutation is found in proximal colon tumors with MLH1 
methylation (80% of cases), while in tumors from hereditary 
nonpolyposis colorectal cancer (HNPCC) cases with MLH1, 
MSH2 or MSH6 germline mutations, no BRAF mutations are 
detected. Because of this it has been proposed that mutation 
of BRAF at V600E can be used as an exclusion criterion for 
Lynch Syndrome.  
CpG Island Methylation 
CpG island methylation is another phenomenon which 
may influence progression to colorectal carcinogenesis. 
DNA methylation is present at a low level in almost all colo-
nic carcinomas, and it has been shown in a subset (known as 
the CPG Island Methylator Phenotype “CIMP”, discussed 
below) to occur at a much higher frequency [123]. 
CpG islands are regions of DNA where there are a large 
number of contiguous cytosine (C) and guanine (G) base 
pairs linked by a phosphodiester bond (hence the name 
“CpG”). These areas are found to exist in the promoter re-
gions of genes involved in many functions, but in colorectal 
cancer the DNA repair enzyme MLH1 is such a region [124]. 
Methylation of these promoter regions of these genes leads 
to silencing and therefore non-expression of the gene prod-
uct, leading to the initiation of carcinogenesis. Other genes 
which such regions are involved in all types of sporadic can-
cer include p16, MLH1 and BRCA1 [125].  
In normal colonic mucosa [126], methylation has been 
noted to increase in a linear manner proportional with age. It 
has also been noted in patients with MSI positive colorectal 
cancer [127] and caused by several carcinogens, with vary-
ing levels of methylation such as the tobacco-derived car-
cinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone 
(16.7%), plutonium (81.8%) and X-rays (38.1%) [126]. 
Toyota et al. [124] carried out a study of the frequency of 
CpG island methylation in colorectal cancer lines. They 
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found that there were two main distinct patterns of methyla-
tion in colorectal cancer, which they termed Type A (ageing 
specific) and Type C (cancer specific).  
In type A methylation, they found increasing global 
methylation in colorectal cancer lines in relation to age. In 
type C methylation, they noted what they termed a “hyper-
methylator phenotype”, termed CpG Island Methylator Phe-
notype positive (CIMP+).  
They found in cell lines that were CIMP+ there was 
widespread silencing of genes through promoter methylation 
which they hypothesised could also cause inactivation of the 
hMLH1 promoter and thus may play a role in up to 75% of 
sporadic colorectal carcinoma cases that are MSI+. They 
suggested that the mechanism underlying this was a loss of 
protection against methylation through an epigenetic error.  
Weisenberger et al. [123] further contributed to our 
knowledge of the CIMP+ phenotype by carrying out Meth-
ylight quantitive methylation specific PCR assays on a li-
brary set of colorectal carcinomas. They found that they 
could reliably identify tumours with the CIMP+ phenotype 
using a five gene set consisting of CACNA1G, IGF2, NEU-
ROG1, RUNX3 and SOCS1, known collectively as the 
“CIMP Panel” 
A further study by Ogino et al. [128] studied colorectal 
carcinomas collected via the Nurses Health Study. They ex-
amined the methylation status of the CIMP panel, as well as 
two additional genes (CDKN2A and CRABP1) and the pro-
moter region of MGMT (O-6-methylguanine-DNA methyl-
transferase), a gene involved in DNA repair.  
In tumours where 4/5 of the CIMP panel were hyper-
methylated, they found a decrease in the expression of nu-
clear p27 and p53, as well as reduced expression of COX2 
and increased TGFBR2 mutations. They also found using 
their total panel of eight genes to look at promoter methyla-
tion that tumours with between 1-5 methylated genes and 
MSI-low have high levels of methylation of MGMT. They 
have termed this “CIMP-low” (as opposed to CIMP-high 
which is equivalent to CIMP+). 
These findings suggest distinct molecular pathways for 
CIMP-high tumours, and possibly for CIMP-low tumours. 
The underlying cause of this type of mutation is still not 
clear, however the concept of “epimutagens”, substances that 
promote aberrant methylation [129] of promoter regions has 
been postulated as a possible mechanism. Grady [130] sug-
gested that the epimutagen hypothesis would fit well with 
the concept of CIMP-low and CIMP-high, however the 
mechanisms and place of promoter methylation in colorectal 
carcinogenesis is still not fully understood. 
CONCLUSIONS 
In summary, molecular advances over the last 30 years 
have led to an exponential increase in the understanding of 
the molecular mechanisms underlying colorectal carcino-
genesis. However, there is a great deal of further work that 
needs to be done to clarify the precise mechanisms underly-
ing colorectal cancer and its initiation and progression, most 
especially at the adenoma level, before progression to a ma-
lignant lesion occurs. 
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